KLHDC8A: A Potential Drug Target and Biomarker for Delta-EGFR Expression in Lung Cancer

Target Name: KLHDC8A

NCBI ID: G55220

KLHDC8A

KLHDC8A: A Potential Drug Target and Biomarker for Delta-EGFR Expression in Lung Cancer

Lung cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 1.8 million new cases and 500,000 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for advanced stages of lung cancer remains poor. Therefore, identifying new drug targets and biomarkers for early detection and treatment is crucial for improving survival outcomes.

KLHDC8A is a potential drug target and biomarker for delta-EGFR expression in lung cancer. Delta-EGFR expression is a highly sensitive indicator of lung cancer progression and poor prognosis. EGFR (Epidermal Growth Factor Receptor) is a transmembrane receptor that plays a crucial role in cell signaling, including the regulation of cell growth, angiogenesis, and survival. EGFR signaling is also involved in the development and progression of many types of cancer, including lung cancer.

KLHDC8A is a known gene that encodes a protein with high affinity for EGFR signaling. The protein encoded by KLHDC8A has been shown to interact with EGFR and contribute to EGFR signaling. Additionally, KLHDC8A has been shown to promote the formation of EGFR-positive cancer cells in cell culture and animal models. These findings suggest that KLHDC8A may be a promising drug target for lung cancer.

In addition to its potential as a drug target, KLHDC8A has also been shown to be a potential biomarker for lung cancer. The expression of KLHDC8A has been shown to be associated with poor prognosis in lung cancer patients. Additionally, higher KLHDC8A expression has been shown to be associated with the development of brain metastases in lung cancer. These findings suggest that KLHDC8A may be a useful biomarker for monitoring the effectiveness of anti-cancer treatments and identifying patients at risk for recurrence.

Furthermore, KLHDC8A has also been shown to be involved in the regulation of cell adhesion and migration. Adhesion and migration are critical processes that play a crucial role in the development and progression of cancer. Therefore, KLHDC8A may be a potential target for cancer therapies that target these processes.

In conclusion, KLHDC8A is a potential drug target and biomarker for delta-EGFR expression in lung cancer. The high-affinity interaction between KLHDC8A and EGFR, as well as its ability to promote the formation of EGFR-positive cancer cells, suggest that KLHDC8A may be a promising target for lung cancer therapies. Additionally, KLHDC8A has also been shown to be involved in the regulation of cell adhesion and migration, which may make it an attractive target for therapies that target these processes. Further research is needed to confirm these findings and determine the full potential of KLHDC8A as a drug target and biomarker for lung cancer.

Protein Name: Kelch Domain Containing 8A

The "KLHDC8A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHDC8A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets